drugset / Trial / NCT00036205

Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease

NCT00036205

Phase 3 Terminated 984 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective is to assess the long term safety and tolerability of sumanirole as measured by safety labs, ECG monitoring, vital signs, and adverse event reports in subjects with Parkinson's Disease who participated in previous sumanirole studies.

Timeline

Start
2000-08
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject sumanirole Small molecule

Indications